Quarterly report [Sections 13 or 15(d)]

Consolidated Statements of Cash Flows (Unaudited)

v3.25.2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Cash flows from operating activities:    
Net loss $ (10,427,632) $ (4,308,639)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 7,669 9,633
Acquired in-process research and development 114,399 12,000
Amortization of operating lease right-of-use asset 58,777 51,876
Share-based compensation 60,395 170,795
Financing costs related to ChEF Purchase Agreement 520,200 370,426
Non-cash financing costs 3,044 1,732
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets 805,527 623,566
Incentive tax receivable 164,685 266,964
Other assets 7,766 (74,274)
Accounts payable 1,540,535 (455,038)
Accrued expenses and other current liabilities 66,118 (2,034,243)
Operating lease liability (62,027) (53,725)
Deferred income (18,626)
Net cash used in operating activities (7,140,544) (5,437,553)
Cash flows from investing activities:    
Purchases of in-process research and development (12,000) (12,000)
Net cash used in investing activities (12,000) (12,000)
Cash flows from financing activities:    
Proceeds from issuance of common stock, net of issuance costs 7,803,453 3,899,157
Payment of deferred offering costs (15,000)
Payment of financing costs related to ChEF Purchase Agreement (465,200) (157,500)
Proceeds from exercise and modification of warrants, net of issuance costs (13,868) 3,002,968
Net cash provided by financing activities 7,324,385 6,729,625
Net increase in cash 171,841 1,280,072
Cash, beginning of period 149,456 2,274,259
Cash, end of period 321,297 3,554,331
Supplemental disclosure of non-cash operating, investing and financing activities:    
Net settlement of warrants 75
In-process research and development in accrued expenses 102,399
ChEF Purchase Agreement financing costs in accounts payable 40,000 212,926
Deferred offering costs in accounts payable and accrued expenses $ 171,900